<DOC>
	<DOCNO>NCT00000805</DOCNO>
	<brief_summary>PRIMARY : To determine pharmacokinetics , MTD , long-term safety tolerance oral ganciclovir HIV-infected infant , child , adolescent . SECONDARY : To evaluate effect oral ganciclovir virologic parameter CMV . Maintenance treatment intravenous ( IV ) ganciclovir cytomegalovirus retinitis AIDS patient standard therapy , daily IV therapy complicate catheter infection thrombosis . An oral regimen ganciclovir administer safely adult AIDS patient may significant benefit child infant well .</brief_summary>
	<brief_title>A Pharmacokinetic Tolerance Study Oral Ganciclovir HIV-Infected Children With Asymptomatic Cytomegalovirus Infection Low CD4 Cell Counts Quiescent Cytomegalovirus Disease</brief_title>
	<detailed_description>Maintenance treatment intravenous ( IV ) ganciclovir cytomegalovirus retinitis AIDS patient standard therapy , daily IV therapy complicate catheter infection thrombosis . An oral regimen ganciclovir administer safely adult AIDS patient may significant benefit child infant well . Patients assign 1 5 ( PER AMENDMENT 10/24/95 , 4 ) oral ( syrup capsule ) dose level follow single intravenous dose ganciclovir . Treatment continue 72 ( PER AMENDMENT 10/24/95 , 24 week ) week last patient enrol .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : PER AMENDMENT 10/24/95 : Allowed : All antiretroviral agent medication except listed Exclusion Concurrent Medications . Didanosine . However , patient receive drug ( didanosine ganciclovir ) monitor toxicity . Amphotericin B allow require additional monitoring . Patients must : HIV infection . CMV infection . CD4 count &lt; 150 cells/mm3 &lt; 15 percent AND/OR quiescent CMV disease . NO loss sight CMV retinitis . NO acute opportunistic infection . Life expectancy least study completion . Consent parent guardian . NOTE : Infants &lt; 6 month age enrollment must &gt; = 36 week gestational age birth . NOTE : Patients may coenroll ACTG protocol involve administration disallow medication . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Loss sight one eye reason , evidence CMV retinitis eye . Acute chronic diarrhea would affect absorption . Clinical laboratory toxicity grade 3 worse . Concurrent Medication : Excluded : Foscarnet . Acyclovir . Interferon . Myelotoxic agent malignancy condition . Other agent antiCMV activity . ( NOTE : Enrollment patient IVIG must discuss protocol chair . ) Imipenem/cilastatin sodium . Prior Medication : Excluded within 30 day prior study entry : GCSF GMCSF .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Ganciclovir</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>